Despite clinical success in colorectal cancer and head and neck cancer (13, 14), the anti-EGFR antibodies cetuximab and panitumumab have shown limited response rates in TNBCs and unselected patient populations (15, 16), likely due to activation of alternative compensatory pathways and inter-/intra-tumoral heterogeneity in EGFR expression (17). This evidence concerns the gene EGFR and colorectal cancer.